Emivirine (MKC-442) is a failed experimental agent for the treatment of HIV. It is a non-nucleoside reverse transcriptase inhibitor.[1] While emivirine showed promising antiviral activity in vitro, it failed to show sufficient efficacy in human trials. However it is still notable as an early proof of concept, which led to the discovery of a number of related antiviral drugs.[2]

References

  1. CID 65013 from PubChem
  2. Serge Van Calenbergh & Piet Herdewijn (February 25, 2005). "A heterogeneous collection of novel antiviral pyrimidines". Expert Opinion on Therapeutic Patents. 10 (3): 289–295. doi:10.1517/13543776.10.3.289.